Roth Capital Estimates ChromaDex's Q2 Earnings (NASDAQ:CDXC)

ChromaDex Co. (NASDAQ:CDXC - Free Report) - Analysts at Roth Capital lowered their Q2 2025 earnings per share (EPS) estimates for shares of ChromaDex in a research report issued to clients and investors on Friday, November 1st. Roth Capital analyst S. Mcgowan now expects that the company will post earnings per share of $0.00 for the quarter, down from their previous forecast of $0.01. The consensus estimate for ChromaDex's current full-year earnings is $0.01 per share. Roth Capital also issued estimates for ChromaDex's Q3 2025 earnings at $0.01 EPS, Q4 2025 earnings at $0.01 EPS, Q1 2026 earnings at $0.01 EPS, Q2 2026 earnings at $0.02 EPS, Q3 2026 earnings at $0.03 EPS and FY2026 earnings at $0.08 EPS.

ChromaDex (NASDAQ:CDXC - Get Free Report) last released its quarterly earnings data on Thursday, October 31st. The company reported $0.02 earnings per share (EPS) for the quarter. ChromaDex had a return on equity of 5.06% and a net margin of 1.62%. The company had revenue of $25.58 million during the quarter, compared to the consensus estimate of $23.70 million. During the same quarter in the prior year, the firm posted ($0.01) earnings per share.

Separately, HC Wainwright lifted their target price on ChromaDex from $6.00 to $8.00 and gave the stock a "buy" rating in a report on Monday.

ChromaDex Stock Performance

Shares of NASDAQ:CDXC traded down $0.12 during mid-day trading on Monday, reaching $5.74. 3,897,021 shares of the company's stock were exchanged, compared to its average volume of 492,245. The firm has a market capitalization of $435.84 million, a price-to-earnings ratio of 597.60 and a beta of 1.88. ChromaDex has a twelve month low of $1.32 and a twelve month high of $6.18. The business's fifty day moving average price is $3.53 and its 200-day moving average price is $3.23.

Insider Transactions at ChromaDex

In other news, Director Kristin Patrick sold 23,000 shares of the business's stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $3.57, for a total value of $82,110.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 9.64% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of CDXC. Miracle Mile Advisors LLC acquired a new position in shares of ChromaDex during the 2nd quarter valued at $27,000. The Manufacturers Life Insurance Company acquired a new position in shares of ChromaDex during the 2nd quarter valued at $31,000. Merriman Wealth Management LLC acquired a new position in shares of ChromaDex during the 2nd quarter valued at $32,000. Lazard Asset Management LLC acquired a new position in shares of ChromaDex during the 1st quarter valued at $43,000. Finally, SG Americas Securities LLC acquired a new position in shares of ChromaDex during the 1st quarter valued at $54,000. Institutional investors and hedge funds own 15.41% of the company's stock.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.